Selected research
Industry Research
Hyperimmune Serum Industry Research Report 2026
Market perspective
The global Hyperimmune Serum market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hyperimmune Serum is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hyperimmune Serum is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hyperimmune Serum is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hyperimmune Serum include ADMA Biologics, Biotest, CBPO, CNBG, CSL Behring, Emergent (Cangene), Grifols, Kamada and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hyperimmune Serum market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hyperimmune Serum Market by Company
ADMA Biologics
Biotest
CBPO
CNBG
CSL Behring
Emergent (Cangene)
Grifols
Kamada
Kedrion
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
Hyperimmune Serum Segment by Type
Rho(D) Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Hepatitis B Immunoglobulins
Other
Hyperimmune Serum Segment by Application
Government Institutions
Private Sector
Other
Hyperimmune Serum Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Serum market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Serum and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Serum.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hyperimmune Serum manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hyperimmune Serum by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hyperimmune Serum in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rho(D) Immunoglobulins
- Rabies Immunoglobulins
- Tetanus Immunoglobulins
- Hepatitis B Immunoglobulins
- Other
Applications
- Government Institutions
- Private Sector
- Other
Companies covered
- ADMA Biologics
- Biotest
- CBPO
- CNBG
- CSL Behring
- Emergent (Cangene)
- Grifols
- Kamada
- Kedrion
- Hualan Bio
- Shanghai RAAS
- Sichuan Yuanda Shuyang
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hyperimmune Serum Market Size (2021-2032)
- 2.2.2 Global Hyperimmune Serum Sales (2021-2032)
- 2.2.3 Global Hyperimmune Serum Market Average Price (2021-2032)
- 2.3 Hyperimmune Serum by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rho(D) Immunoglobulins
- 2.3.3 Rabies Immunoglobulins
- 2.3.4 Tetanus Immunoglobulins
- 2.3.5 Hepatitis B Immunoglobulins
- 2.3.6 Other
- 2.4 Hyperimmune Serum by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Government Institutions
- 2.4.3 Private Sector
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hyperimmune Serum Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hyperimmune Serum Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Hyperimmune Serum Revenue of Manufacturers (2021-2026)
- 3.4 Global Hyperimmune Serum Average Price by Manufacturers (2021-2026)
- 3.5 Global Hyperimmune Serum Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hyperimmune Serum, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hyperimmune Serum, Product Type & Application
- 3.8 Global Manufacturers of Hyperimmune Serum, Established Date
- 3.9 Global Hyperimmune Serum Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ADMA Biologics
- 4.1.1 ADMA Biologics Company Information
- 4.1.2 ADMA Biologics Business Overview
- 4.1.3 ADMA Biologics Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ADMA Biologics Hyperimmune Serum Product Portfolio
- 4.1.5 ADMA Biologics Recent Developments
- 4.2 Biotest
- 4.2.1 Biotest Company Information
- 4.2.2 Biotest Business Overview
- 4.2.3 Biotest Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biotest Hyperimmune Serum Product Portfolio
- 4.2.5 Biotest Recent Developments
- 4.3 CBPO
- 4.3.1 CBPO Company Information
- 4.3.2 CBPO Business Overview
- 4.3.3 CBPO Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CBPO Hyperimmune Serum Product Portfolio
- 4.3.5 CBPO Recent Developments
- 4.4 CNBG
- 4.4.1 CNBG Company Information
- 4.4.2 CNBG Business Overview
- 4.4.3 CNBG Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CNBG Hyperimmune Serum Product Portfolio
- 4.4.5 CNBG Recent Developments
- 4.5 CSL Behring
- 4.5.1 CSL Behring Company Information
- 4.5.2 CSL Behring Business Overview
- 4.5.3 CSL Behring Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CSL Behring Hyperimmune Serum Product Portfolio
- 4.5.5 CSL Behring Recent Developments
- 4.6 Emergent (Cangene)
- 4.6.1 Emergent (Cangene) Company Information
- 4.6.2 Emergent (Cangene) Business Overview
- 4.6.3 Emergent (Cangene) Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Emergent (Cangene) Hyperimmune Serum Product Portfolio
- 4.6.5 Emergent (Cangene) Recent Developments
- 4.7 Grifols
- 4.7.1 Grifols Company Information
- 4.7.2 Grifols Business Overview
- 4.7.3 Grifols Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Grifols Hyperimmune Serum Product Portfolio
- 4.7.5 Grifols Recent Developments
- 4.8 Kamada
- 4.8.1 Kamada Company Information
- 4.8.2 Kamada Business Overview
- 4.8.3 Kamada Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kamada Hyperimmune Serum Product Portfolio
- 4.8.5 Kamada Recent Developments
- 4.9 Kedrion
- 4.9.1 Kedrion Company Information
- 4.9.2 Kedrion Business Overview
- 4.9.3 Kedrion Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Kedrion Hyperimmune Serum Product Portfolio
- 4.9.5 Kedrion Recent Developments
- 4.10 Hualan Bio
- 4.10.1 Hualan Bio Company Information
- 4.10.2 Hualan Bio Business Overview
- 4.10.3 Hualan Bio Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hualan Bio Hyperimmune Serum Product Portfolio
- 4.10.5 Hualan Bio Recent Developments
- 4.11 Shanghai RAAS
- 4.11.1 Shanghai RAAS Company Information
- 4.11.2 Shanghai RAAS Business Overview
- 4.11.3 Shanghai RAAS Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Shanghai RAAS Hyperimmune Serum Product Portfolio
- 4.11.5 Shanghai RAAS Recent Developments
- 4.12 Sichuan Yuanda Shuyang
- 4.12.1 Sichuan Yuanda Shuyang Company Information
- 4.12.2 Sichuan Yuanda Shuyang Business Overview
- 4.12.3 Sichuan Yuanda Shuyang Hyperimmune Serum Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sichuan Yuanda Shuyang Hyperimmune Serum Product Portfolio
- 4.12.5 Sichuan Yuanda Shuyang Recent Developments
5 Global Hyperimmune Serum Market Scenario by Region
- 5.1 Global Hyperimmune Serum Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hyperimmune Serum Sales by Region: 2021-2032
- 5.2.1 Global Hyperimmune Serum Sales by Region: 2021-2026
- 5.2.2 Global Hyperimmune Serum Sales by Region: 2027-2032
- 5.3 Global Hyperimmune Serum Revenue by Region: 2021-2032
- 5.3.1 Global Hyperimmune Serum Revenue by Region: 2021-2026
- 5.3.2 Global Hyperimmune Serum Revenue by Region: 2027-2032
- 5.4 North America Hyperimmune Serum Market Facts & Figures by Country
- 5.4.1 North America Hyperimmune Serum Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hyperimmune Serum Sales by Country (2021-2032)
- 5.4.3 North America Hyperimmune Serum Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hyperimmune Serum Market Facts & Figures by Country
- 5.5.1 Europe Hyperimmune Serum Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hyperimmune Serum Sales by Country (2021-2032)
- 5.5.3 Europe Hyperimmune Serum Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Hyperimmune Serum Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hyperimmune Serum Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hyperimmune Serum Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hyperimmune Serum Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hyperimmune Serum Market Facts & Figures by Country
- 5.7.1 South America Hyperimmune Serum Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hyperimmune Serum Sales by Country (2021-2032)
- 5.7.3 South America Hyperimmune Serum Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hyperimmune Serum Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hyperimmune Serum Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hyperimmune Serum Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hyperimmune Serum Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hyperimmune Serum Sales by Type (2021-2032)
- 6.1.1 Global Hyperimmune Serum Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Hyperimmune Serum Sales Market Share by Type (2021-2032)
- 6.2 Global Hyperimmune Serum Revenue by Type (2021-2032)
- 6.2.1 Global Hyperimmune Serum Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hyperimmune Serum Revenue Market Share by Type (2021-2032)
- 6.3 Global Hyperimmune Serum Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hyperimmune Serum Sales by Application (2021-2032)
- 7.1.1 Global Hyperimmune Serum Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Hyperimmune Serum Sales Market Share by Application (2021-2032)
- 7.2 Global Hyperimmune Serum Revenue by Application (2021-2032)
- 7.2.1 Global Hyperimmune Serum Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hyperimmune Serum Revenue Market Share by Application (2021-2032)
- 7.3 Global Hyperimmune Serum Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hyperimmune Serum Value Chain Analysis
- 8.1.1 Hyperimmune Serum Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hyperimmune Serum Production Mode & Process
- 8.2 Hyperimmune Serum Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hyperimmune Serum Distributors
- 8.2.3 Hyperimmune Serum Customers
9 Global Hyperimmune Serum Analyzing Market Dynamics
- 9.1 Hyperimmune Serum Industry Trends
- 9.2 Hyperimmune Serum Industry Drivers
- 9.3 Hyperimmune Serum Industry Opportunities and Challenges
- 9.4 Hyperimmune Serum Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst